Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV-1-infection: early-phase trial registry
24 of 72 indexed HIV-1-infection trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #191 of 28,707 conditions by registered trial count.
72 US clinical trials · 24 currently recruiting · #191 of 28,707 conditions by registered trial count
HIV-1-infection: 72 US clinical trials tracked, 24 recruiting.
HIV-1-infection is the subject of 72 registered US clinical trials on ClinicalTrials.gov, 24 of them currently open to new participants. 15 are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most active sponsor is Gilead Sciences, running 20 of these trials.
Enrollment posture brief
Registry condition hiv-1-infection
OPEN 24 | RECR 33% | LATE 15 | EARLY 40 | RANK #191 | SPON 20
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
HIV-1-infection lists 24 open slots (33% of 72 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HIV-1-infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HIV-1-infection is recruiting below its size-band peers.
24 of 72 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HIV-1-infection research.
Gilead Sciences accounts for 20 of 72 trials (27.8%). 35 distinct sponsors appear on at least one study for this condition label.
-
Typical HIV-1-infection enrolment sits around 80 participants.
Median target enrolment is 80 among the 72 trials that report a genuine target (sentinel values excluded). 40 of those (55.6%) plan for fewer than 100 participants.
-
HIV-1-infection research is mostly interventional.
62 interventional and 10 observational studies make up this index (86.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
72 total, page 1 of 2
Triage Survey for Infectious Disease Eligibility
Brooklyn Clinical Research
NCT06492187
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
NCT07293559
Acceptance and Commitment Therapy for HIV+ Hazardous Drinkers
Syracuse University
NCT06648629
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
University of Pennsylvania
NCT04480554
Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US
Duke University
NCT05129345
Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)
Florida International University
NCT05136703
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
University of California, San Diego
NCT04883255
Ending the Epidemic Interventions in the Dental Setting - UH3
Columbia University
NCT06890988
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
Massachusetts General Hospital
NCT06554717
Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05660980
Improving Coronary Vascular Health in Women
Massachusetts General Hospital
NCT06843902
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
Gilead Sciences
NCT06532656
HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study
TaiMed Biologics
NCT07215468
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
BioNTech SE
NCT07392372
PrEPsmart 2-1-1 Pilot
Public Health Foundation Enterprises
NCT06631365
A Clinical Trial of STP0404 in Adults With HIV-1 Infection
ST Pharm Co.
NCT05869643
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06071767
Study of GS-3242 in Participants With HIV-1; Substudy-05
Gilead Sciences
NCT07001319
Observational PIC Destination Cohort
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT05985642
PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)
University of California, San Francisco
NCT03729752
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
Gilead Sciences
NCT07055451
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
Gilead Sciences
NCT06749054
Safety Study of MucoCept-CVN
Craig Cohen, MD, MPH
NCT07181486
Pharmacokinetics Distribution of Raltegravir by PET/MR
University of California, San Francisco
NCT03174977
Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
Merck Sharp & Dohme
NCT04776252
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen
Gilead Sciences
NCT05502341
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
Gilead Sciences
NCT06613685
Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
Gilead Sciences
NCT06544733
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
Gilead Sciences
NCT06630286
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
Gilead Sciences
NCT06630299
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
Gilead Sciences
NCT06333808
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
Merck Sharp & Dohme
NCT05631093
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
Merck Sharp & Dohme
NCT05705349
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
Merck Sharp & Dohme
NCT05630755
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1
Gilead Sciences
NCT02881320
Bictegravir in the Elderly Living With HIV (BICEP)
State University of New York at Buffalo
NCT05064020
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
Gilead Sciences
NCT05052996
Impact of HIV-1 and Aging on Mucosal Vaccine Responses
VA Eastern Colorado Health Care System
NCT03729778
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
Gilead Sciences
NCT04150068
Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05471076
Healthy Lifestyles: A Home Based Physical Activity Intervention in Persons Living With HIV
Georgetown University
NCT05896852
A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1-RNA in Adults Without HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06919016
Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study
Orlando Immunology Center
NCT05220358
Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients
Calimmune
NCT02390297
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Gilead Sciences
NCT02607930
Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)
Merck Sharp & Dohme
NCT04233879
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
Gilead Sciences
NCT01252940
Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT03512210
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT01400412
Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
Merck Sharp & Dohme
NCT03272347
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 21 |
| Phase 3 | 12 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on HIV-1-infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HIV-1-infection trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HIV-1-infection page
72 registered trials, 24 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 24 HIV-1-infection trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Gilead Sciences sponsors the most HIV-1-infection trials on record, review their full trial history before evaluating a specific study. See Gilead Sciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV-1-infection condition card totals 72 registered trials; most-linked intervention B/F/TAF; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.